When the FDA says stop, MethodSense helps you move forward
Whether you’re facing a Refuse-to-Accept (RTA), additional information (AI) request, or post-audit finding, we bring clarity and speed to your recovery plan.
Remediate and reformat rejected submissions
We pinpoint what went wrong, and how to fix it fast. When the FDA says no, you don’t just need edits. You need a strategy. We evaluate agency feedback, rework your submission structure, and help you present a clear, compliant, and compelling package that addresses deficiencies without overcomplicating the narrative. We help you communicate with your stakeholders, board and investors to reassure them and keep them engaged.
Related Services
Regulatory Remediation & FDA Audit Support
Submission Management & Acceleration
Design History & Risk Management
- Analyze RTA checklists or deficiency letters
- Restructure submission documents for compliance
- Prepare justifications and new evidence as needed
Respond to FDA audits or 483s with confidence
We help you address root causes, implement CAPAs, and respond to FDA expectations clearly.A 483 or audit finding isn’t the end. It’s an opportunity to strengthen your systems. We help you draft focused responses, verify your corrective actions, and build documentation that not only satisfies the FDA but also sets you up for long-term compliance.
Related Services
Process Optimization & Supplier Audits
On-Call Quality Support
QMS Implementation
- Draft and refine audit responses
- Conduct internal audits to verify CAPA effectiveness
- Assist with follow-up QMS documentation
Re-align your regulatory strategy and reposition the submission
Sometimes a course correction is the best next step. If your original approach no longer serves your product or goals, we help you recalibrate. From rethinking your intended use or predicate device to exploring new regulatory pathways, we provide strategic guidance and agency coordination that gets your project back on a winning track.
Related Services
Regulatory Pathway Consulting
Pre-Submission & FDA Negotiations
Strategic Partner for Commercialization
- Reevaluate product claims or indications
- Recommend alternative pathways or supportive data
- Manage correspondence with FDA or other agencies